Male androgenetic alopecia male androgenetic alopecia male pattern hair loss dutasteride low-dose dutasteride intermittent regimens intermittent dosing
Conditions
Interventions
oral dutasteride 0.5 mg 1 tab/day on Mon, Wed, Fri
placebo 1 tab/day on Tue, Thur, Sat, Sun
for 24 weeks,oral dutasteride 0.5 mg 1 tab/day on Mon-Fri
placebo 1 tab/day on Sat, Sun
for 24 weeks,oral du
oral dutasteride 0.5 mg 3 times/week,oral dutasteride 0.5 mg 5 times/week,oral dutasteride 0.5 mg once daily
Sponsors
Faculty of medicine, Srinakharinwirot University
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Androgenetic alopecia with mild to moderate severity
Exclusion criteria
Exclusion criteria: 1.History of kidney disease, liver disease, heart failure, or benign prostatic hyperplasia 2.History of breast cancer or prostate cancer, including previously treated cases 3.History of other medical conditions that may cause hair loss, such as anemia, hypo- or hyperthyroidism, systemic lupus erythematosus, malnutrition, and trichotillomania 4.History of treatment for hair loss using other modalities within 3 months prior to enrollment, such as low-level laser/light therapy (LLLT) or platelet-rich plasma (PRP) 5.History of other scalp dermatologic conditions such as psoriasis or tinea capitis 6.History of depression or suicidal ideation. Participants screened using the 2Q and 9Q depression screening tools with a score 7 or above will be excluded. 7.Individuals with psychiatric disorders, including trichotillomania, will also be excluded 8.History of allergy to 5 alpha reductase inhibitors or any inactive ingredients in the study medication. Family history of breast cancer or prostate cancer in first-degree relatives 9.9.History of using oral medications that may affect hair growth within 6 months prior to enrollment, including minoxidil, finasteride, dutasteride, flutamide, spironolactone, cyproterone acetate, cimetidine, diazoxide, cyclosporine, ketoconazole, anticonvulsants, and chemotherapeutic agents. Exception: prior use of dutasteride within 12 months before enrollment 10.History of using topical medications affecting hair growth within 3 months prior to enrollment, including minoxidil and finasteride 11.History of using hair growth promoting products within 1 month prior to enrollment, including ketoconazole shampoo
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in hair density using videodermoscopy 24 weeks micrographs from videodermoscopy | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in hair diameter using videodermoscopy 24 weeks micrographs from videodermoscopy,Overall clinical changes from baseline 24 weeks paired global photographs,patient satisfaction 24 weeks 10-point visual analog scale,adverse events 24 weeks interview, questionnaire,Change from baseline in serum DHT 24 weeks ELISA test for serum DHT,Change from baseline in serum PSA 24 weeks chemiluminescent immunoassay (CLIA) for serum PSA | — |
Countries
Thailand
Contacts
Public ContactSaranya Khunkhet
Srinakharinwirot University
Outcome results
None listed